Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Cyrille HulinJavier de la RubiaMeletios A DimopoulosEvangelos TerposEirini KatodritouVania Tietsche de Moraes HungriaHadewijch De SamblanxAnne-Marie StoppaJesper AagesenDeniz SarginAnastasia SioniAndrew BelchJoris DielsRobert A OlieDon RobinsonAnna PotamianouHelgi van de VeldeMichel Delforge

Published in: Health science reports (2018)

These data suggest that retreatment with bortezomib is a feasible option for patients with relapsed/refractory MM.

Keyphrases

multiple myeloma
clinical practice
electronic health record
big data
acute lymphoblastic leukemia
data analysis
hodgkin lymphoma
newly diagnosed